AveXis Inc. (AVXS) Shares Down 3.2%
Shares of AveXis Inc. (NASDAQ:AVXS) dropped 3.2% on Tuesday . The stock traded as low as $41.03 and last traded at $42.16, with a volume of 343,823 shares trading hands. The stock had previously closed at $43.57.
AVXS has been the subject of several research analyst reports. Jefferies Group raised shares of AveXis from a “hold” rating to a “buy” rating and set a $42.00 price target for the company in a research note on Friday, August 12th. Goldman Sachs Group Inc. lifted their price target on shares of AveXis from $28.00 to $47.00 and gave the company a “buy” rating in a research note on Friday, May 13th. Zacks Investment Research raised shares of AveXis from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a research note on Thursday, May 12th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $60.00 price target on shares of AveXis in a research note on Monday, May 9th. Six analysts have rated the stock with a buy rating, AveXis has a consensus rating of “Buy” and a consensus price target of $45.40.
The firm’s market capitalization is $898.43 million. The company has a 50-day moving average price of $37.19 and a 200 day moving average price of $31.63.
AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, August 11th. The company reported ($0.68) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.77) by $0.09. On average, analysts forecast that AveXis Inc. will post ($3.64) EPS for the current fiscal year.
AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.